Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP015K in RA patients with inadequate response to MTX
NCT03660059Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of peficitinib in rheumatoid arthritis (RA), sponsored by Astellas Pharma. Started Sep 2018; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03660059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660059.